Agilent Technologies, Inc. (NYSE:A) is Freedom Together Foundation’s 9th Largest Position

Freedom Together Foundation lessened its position in shares of Agilent Technologies, Inc. (NYSE:A) by 79.9% during the 4th quarter, Holdings Channel reports. The firm owned 20,357 shares of the medical research company’s stock after selling 81,000 shares during the quarter. Agilent Technologies comprises 0.3% of Freedom Together Foundation’s portfolio, making the stock its 9th largest holding. Freedom Together Foundation’s holdings in Agilent Technologies were worth $2,735,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. CKW Financial Group boosted its holdings in Agilent Technologies by 114.9% in the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 100 shares during the last quarter. Global X Japan Co. Ltd. boosted its stake in shares of Agilent Technologies by 161.1% in the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock worth $25,000 after buying an additional 116 shares during the last quarter. Redwood Park Advisors LLC purchased a new stake in shares of Agilent Technologies in the fourth quarter worth about $27,000. Lee Danner & Bass Inc. acquired a new stake in Agilent Technologies during the fourth quarter worth about $29,000. Finally, Hanson & Doremus Investment Management raised its position in Agilent Technologies by 66.5% during the fourth quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 105 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. TD Cowen lifted their target price on shares of Agilent Technologies to $135.00 and gave the company a “buy” rating in a report on Thursday, April 10th. Wells Fargo & Company decreased their price objective on shares of Agilent Technologies from $155.00 to $135.00 and set an “overweight” rating for the company in a research report on Thursday, April 17th. Jefferies Financial Group dropped their target price on Agilent Technologies from $135.00 to $116.00 and set a “hold” rating on the stock in a research report on Monday, April 21st. Barclays reduced their price target on Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Finally, Robert W. Baird dropped their price objective on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Agilent Technologies currently has an average rating of “Moderate Buy” and a consensus target price of $143.00.

Agilent Technologies Stock Performance

Shares of NYSE:A opened at $106.93 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66. Agilent Technologies, Inc. has a 1 year low of $96.43 and a 1 year high of $155.35. The firm has a market capitalization of $30.49 billion, a PE ratio of 24.58, a P/E/G ratio of 3.06 and a beta of 1.27. The business’s 50 day moving average price is $111.53 and its 200-day moving average price is $128.80.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. The company had revenue of $1.68 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. As a group, equities research analysts expect that Agilent Technologies, Inc. will post 5.54 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st were issued a $0.248 dividend. The ex-dividend date was Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.93%. Agilent Technologies’s payout ratio is 22.76%.

Insiders Place Their Bets

In related news, Director Daniel K. Podolsky sold 1,819 shares of the company’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the transaction, the director now directly owns 35,737 shares in the company, valued at approximately $4,161,931.02. This represents a 4.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Rodney Gonsalves sold 1,908 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the sale, the vice president now directly owns 21,786 shares of the company’s stock, valued at approximately $2,657,456.28. This trade represents a 8.05 % decrease in their position. The disclosure for this sale can be found here.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.